""This is a retrospective analysis looking at the potential association of PSA progression with imaging progression," said study co‑author Maha Hussain, MD. "PSA is a biomarker. It's a test that we do across the spectrum of prostate cancer.""
""What was interesting is that in both of these trials, there were patients who actually progressed, but their PSA never went up.""
A large analysis of two clinical trials involving over 2,500 patients revealed that prostate cancer progression can be identified through imaging scans despite stable PSA levels. This finding challenges the reliance on PSA as the sole biomarker for monitoring treatment response. The study indicated that radiographic progression occurred more frequently in patients treated with enzalutamide and androgen-deprivation therapy compared to control treatments. The results suggest a need for reevaluating monitoring strategies in prostate cancer management.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]